534 related articles for article (PubMed ID: 24645664)
21. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.
Shen JS; Arning E; West ML; Day TS; Chen S; Meng XL; Forni S; McNeill N; Goker-Alpan O; Wang X; Ashcraft P; Moore DF; Cheng SH; Schiffmann R; Bottiglieri T
Hum Mol Genet; 2017 Mar; 26(6):1182-1192. PubMed ID: 28158561
[TBL] [Abstract][Full Text] [Related]
22. [Update on the treatment of Fabry's disease: pathophysiological concepts].
Politei JM
Rev Neurol; 2010 Nov; 51(9):561-70. PubMed ID: 20979036
[TBL] [Abstract][Full Text] [Related]
23. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
24. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
25. Renal involvement in Fabry's disease.
Okuda S
Intern Med; 2000 Aug; 39(8):601-2. PubMed ID: 10939529
[No Abstract] [Full Text] [Related]
26. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
[TBL] [Abstract][Full Text] [Related]
27. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
28. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
30. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
31. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease: A fundamental genetic modifier of cardiac function.
Tadevosyan A
Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691
[TBL] [Abstract][Full Text] [Related]
33. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
34. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
35. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
36. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
37. Clinical, histological and molecular characteristics of Mexican patients with Fabry disease and significant renal involvement.
Ramos-Kuri M; Olvera D; Morales JJ; Rodriguez-Espino BA; Lara-Mejía A; De Los Ríos D; Obrador GT; Granados J; Correa-Rotter R
Arch Med Res; 2014 Apr; 45(3):257-62. PubMed ID: 24656905
[TBL] [Abstract][Full Text] [Related]
38. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
[TBL] [Abstract][Full Text] [Related]
39. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
Terryn W; Cochat P; Froissart R; Ortiz A; Pirson Y; Poppe B; Serra A; Van Biesen W; Vanholder R; Wanner C
Nephrol Dial Transplant; 2013 Mar; 28(3):505-17. PubMed ID: 23234755
[TBL] [Abstract][Full Text] [Related]
40. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
